These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20007620)

  • 1. A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals.
    Boers M
    Ann Rheum Dis; 2010 Jan; 69(1):4-6. PubMed ID: 20007620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy assessment in trials of combination therapy for rheumatoid arthritis.
    Johnson K
    J Rheumatol Suppl; 1996 Mar; 44():107-9. PubMed ID: 8833066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism.
    Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
    Pham B; Cranney A; Boers M; Verhoeven AC; Wells G; Tugwell P
    J Rheumatol; 1999 Mar; 26(3):712-6. PubMed ID: 10090188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents.
    Boers M
    Ann Rheum Dis; 2010 Jan; 69(1):186-92. PubMed ID: 19773287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis.
    Venkateshan SP; Sidhu S; Malhotra S; Pandhi P
    Pharmacology; 2009; 83(1):1-9. PubMed ID: 18957873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
    Pincus T; Sokka T
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii32-ii39. PubMed ID: 15479869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for rheumatoid arthritis.
    Roberts LJ
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15602032
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.